Send a Tweet
Most Popular Choices
Share on Facebook 5 Share on Twitter 1 Printer Friendly Page More Sharing
OpEdNews Op Eds   

Of Rotten Apples and Rotten Systems

By       (Page 1 of 2 pages)     (# of views)   1 comment
Author 47089
Follow Me on Twitter     Message Robert Reich
Become a Fan
  (128 fans)

Reprinted from Robert Reich Blog

Martin Shkreli: .I Would've Raised Prices Higher.
Martin Shkreli: .I Would've Raised Prices Higher.
(Image by Forbes, Channel: forbes)
  Details   DMCA
>

Martin Shkreli, the former hedge-fund manager turned pharmaceutical CEO who was arrested last week, has been described as a sociopath and worse.

In reality, he's a brasher and larger version of what others in finance and corporate suites do all the time.

Federal prosecutors are charging him with conning wealthy investors.

Lying to investors is illegal, of course, but it's perfectly normal to use hype to lure rich investors into hedge funds. And the line between the two isn't always distinct.

Hedge funds are lightly regulated on the assumption that investors are sophisticated and can take care of themselves.

Perhaps prosecutors went after Shkreli because they couldn't nail him for his escapades as a pharmaceutical executive, which were completely legal -- although vile.

Shkreli took over a company with the rights to a 62-year-old drug used to treat toxoplasmosis, a devastating parasitic infection that can cause brain damage in babies and people with AIDS. He then promptly raised its price from $13.50 to $750 a pill.

When the media and politicians went after him, Shkreli was defiant, saying "our shareholders expect us to make as much as money as possible." He said he wished he had raised the price even higher.

That was too much even for the Pharmaceutical Research and Manufacturers of America, Big Pharma's trade group, which complained indignantly that Shkreli's company was just an investment vehicle "masquerading" as a pharmaceutical company.

Maybe Big Pharma doesn't want to admit most pharmaceutical companies have become investment vehicles. If they didn't deliver for their investors they'd be taken over by "activist" investors and private-equity partners who would.

The hypocrisy is stunning. Just three years ago, Forbes Magazine praised Shkreli as one of its "30 under 30 in Finance" who was "battling billionaires and entrenched drug industry executives."

Last month, Shkreli got control of a company with rights to a cheap drug used for decades to treat Chagas' disease in Latin America. His aim was to get the drug approved in the United States and charge tens of thousands of dollars for a course of treatment.

Investors who backed Shkreli in this venture did well. The company's share price initially shot up from under $2 to more than $40.

While other pharmaceutical companies don't raise their drug prices fiftyfold in one fell swoop, as did Shkreli, they would if they thought it would lead to fat profits.

Most have been increasing their prices more than 10 percent a year -- still far faster than inflation -- on drugs used on common diseases like cancer, high cholesterol, and diabetes.

Next Page  1  |  2

 

Must Read 2   News 1   Supported 1  
Rate It | View Ratings

Robert Reich Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Robert Reich, former U.S. Secretary of Labor and Professor of Public Policy at the University of California at Berkeley, has a new film, "Inequality for All," to be released September 27. He blogs at www.robertreich.org.

Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEdNews Newsletter
Name
Email
   (Opens new browser window)
 

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Trump Cornered

The Republican's Big Lies About Jobs (And Why Obama Must Repudiate Them)

Paul Ryan Still Doesn't Get It

What Mitt Romney Really Represents

What to Do About Disloyal Corporations

The Gas Wars